You are here

  • Home
  • Archive
  • Volume 9, Issue 10
  • JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma

 

Online download statistics by month:

Online download statistics by month: October 2021 to September 2025

AbstractFullPdf
Oct 202127227261
Nov 2021776772275
Dec 202115615742
Jan 202210811141
Feb 2022676726
Mar 2022787832
Apr 202211311436
May 2022929425
Jun 2022979920
Jul 202211011124
Aug 202210010119
Sep 202211511538
Oct 202210510651
Nov 202210610732
Dec 2022939328
Jan 2023778020
Feb 202310610722
Mar 2023464822
Apr 2023323325
May 2023404110
Jun 2023494914
Jul 2023303010
Aug 2023434318
Sep 202339398
Oct 2023282817
Nov 202349498
Dec 2023383818
Jan 2024353615
Feb 2024464617
Mar 2024575793
Apr 2024414230
May 2024909013
Jun 2024504927
Jul 2024606133
Aug 2024333027
Sep 2024383824
Oct 2024959516
Nov 2024878818
Dec 2024899187
Jan 2025939322
Feb 2025828219
Mar 2025808131
Apr 202511811837
May 2025899030
Jun 2025727215
Jul 2025110
Sep 2025110
Total422242431496